Annual Cash & Cash Equivalents
$20.77 M
-$8.21 M-28.32%
31 December 2023
Summary:
Evogene annual cash & cash equivalents is currently $20.77 million, with the most recent change of -$8.21 million (-28.32%) on 31 December 2023. During the last 3 years, it has fallen by -$25.46 million (-55.07%). EVGN annual cash & cash equivalents is now -78.24% below its all-time high of $95.45 million, reached on 31 December 2013.EVGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$11.32 M
+$1.83 M+19.33%
30 September 2024
Summary:
Evogene quarterly cash and cash equivalents is currently $11.32 million, with the most recent change of +$1.83 million (+19.33%) on 30 September 2024. Over the past year, it has dropped by -$16.01 million (-58.59%). EVGN quarterly cash and cash equivalents is now -88.14% below its all-time high of $95.45 million, reached on 31 December 2013.EVGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EVGN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -28.3% | -58.6% |
| 3 y3 years | -55.1% | -69.9% |
| 5 y5 years | +257.5% | -31.3% |
EVGN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -55.1% | at low | -69.9% | +19.3% |
| 5 y | 5 years | -55.1% | +257.5% | -75.5% | +19.3% |
| alltime | all time | -78.2% | +541.9% | -88.1% | +360.6% |
Evogene Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $11.32 M(+19.3%) |
| June 2024 | - | $9.48 M(-20.4%) |
| Mar 2024 | - | $11.91 M(-42.6%) |
| Dec 2023 | $20.77 M(-28.3%) | $20.77 M(-24.0%) |
| Sept 2023 | - | $27.33 M(+35.1%) |
| June 2023 | - | $20.23 M(-12.0%) |
| Mar 2023 | - | $23.00 M(-20.6%) |
| Dec 2022 | $28.98 M(-10.3%) | $28.98 M(-9.0%) |
| Sept 2022 | - | $31.86 M(+10.4%) |
| June 2022 | - | $28.87 M(-19.8%) |
| Mar 2022 | - | $36.01 M(+11.4%) |
| Dec 2021 | $32.33 M(-30.1%) | $32.33 M(-14.1%) |
| Sept 2021 | - | $37.63 M(-12.0%) |
| June 2021 | - | $42.76 M(+10.6%) |
| Mar 2021 | - | $38.64 M(-16.4%) |
| Dec 2020 | $46.23 M(+33.0%) | $46.23 M(+11.4%) |
| Sept 2020 | - | $41.49 M(+33.5%) |
| June 2020 | - | $31.07 M(-2.9%) |
| Mar 2020 | - | $32.01 M(-7.9%) |
| Dec 2019 | $34.75 M(+498.1%) | $34.75 M(+111.0%) |
| Sept 2019 | - | $16.47 M(+16.8%) |
| June 2019 | - | $14.10 M(+114.0%) |
| Mar 2019 | - | $6.59 M(+13.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $5.81 M(+69.1%) | $5.81 M(+1.8%) |
| Sept 2018 | - | $5.71 M(-61.2%) |
| June 2018 | - | $14.73 M(+175.2%) |
| Mar 2018 | - | $5.35 M(+55.8%) |
| Dec 2017 | $3.44 M(+6.1%) | $3.44 M(+39.8%) |
| Sept 2017 | - | $2.46 M(-57.3%) |
| June 2017 | - | $5.76 M(+75.0%) |
| Mar 2017 | - | $3.29 M(+1.7%) |
| Dec 2016 | $3.24 M(-68.3%) | $3.24 M(-40.5%) |
| Sept 2016 | - | $5.44 M(-1.7%) |
| June 2016 | - | $5.53 M(+38.8%) |
| Mar 2016 | - | $3.98 M(-61.0%) |
| Dec 2015 | $10.22 M(+96.1%) | $10.22 M(-13.7%) |
| Sept 2015 | - | $11.85 M(+49.0%) |
| June 2015 | - | $7.95 M(-21.0%) |
| Mar 2015 | - | $10.07 M(+93.1%) |
| Dec 2014 | $5.21 M(-94.5%) | $5.21 M(-65.2%) |
| Sept 2014 | - | $14.96 M(+71.7%) |
| June 2014 | - | $8.72 M(-41.3%) |
| Mar 2014 | - | $14.86 M(-84.4%) |
| Dec 2013 | $95.45 M(+293.4%) | $95.45 M(+473.1%) |
| Sept 2013 | - | $16.66 M(-1.4%) |
| June 2013 | - | $16.88 M(-30.4%) |
| Dec 2012 | $24.26 M | $24.26 M |
FAQ
- What is Evogene annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Evogene?
- What is Evogene annual cash & cash equivalents year-on-year change?
- What is Evogene quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Evogene?
- What is Evogene quarterly cash and cash equivalents year-on-year change?
What is Evogene annual cash & cash equivalents?
The current annual cash & cash equivalents of EVGN is $20.77 M
What is the all time high annual cash & cash equivalents for Evogene?
Evogene all-time high annual cash & cash equivalents is $95.45 M
What is Evogene annual cash & cash equivalents year-on-year change?
Over the past year, EVGN annual cash & cash equivalents has changed by -$8.21 M (-28.32%)
What is Evogene quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EVGN is $11.32 M
What is the all time high quarterly cash and cash equivalents for Evogene?
Evogene all-time high quarterly cash and cash equivalents is $95.45 M
What is Evogene quarterly cash and cash equivalents year-on-year change?
Over the past year, EVGN quarterly cash and cash equivalents has changed by -$16.01 M (-58.59%)